Live News EQUITY M impact Jun 26, 2026, 11:00 AM UTC

AXSM Initiates ADHD Trial

Axsome Therapeutics initiates FOCUS-3 Phase 3 trial of Solriamfetol in adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

SQUAWKNEWS Updated Jun 26, 2026, 11:00 AM UTC

AXSM - Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)